Related Experiment Video
Updated: Apr 17, 2026
3D Organotypic Co-culture Model Supporting Medullary Thymic Epithelial Cell Proliferation, Differentiation and Promiscuous Gene Expression
Published on: July 30, 2015
Irisflorentin modifies properties of mouse bone marrow-derived dendritic cells and reduces the allergic contact
Ru-Huei Fu1, Chia-Wen Tsai, Rong-Tzong Tsai
1Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.
Insights
Irisflorentin, a compound from Belamcanda chinensis, modulates dendritic cell (DC) properties. It reduces inflammatory responses and T-cell activation, showing potential as an immunotherapeutic adjuvant.
Area of Science:
- Immunology
- Pharmacology
- Traditional Chinese Medicine
Background:
- Dendritic cells (DCs) are key regulators of T-cell immunity and tolerance.
- Dysregulated DC activation contributes to harmful immune responses.
- Irisflorentin is an isoflavone from Belamcanda chinensis, used in traditional medicine for inflammation.
Purpose of the Study:
- To investigate irisflorentin's effects on lipopolysaccharide (LPS)-stimulated dendritic cell (DC) maturation in vitro.
- To evaluate irisflorentin's efficacy in a contact hypersensitivity response (CHSR) model in vivo.
- To explore irisflorentin's potential as an immunotherapeutic adjuvant.
Main Methods:
- Assessed irisflorentin's toxicity on mouse bone marrow-derived DCs.
- Measured proinflammatory cytokine production (TNF-α, IL-6, IL-12p70) in LPS-stimulated DCs.
- Analyzed expression of MHC class II, CD40, and CD86 on DCs.
- Evaluated irisflorentin's impact on T-cell proliferation and DC-elicited immune signaling pathways (NF-κB, JNK, p38).
- Assessed irisflorentin's effect on 2,4-dinitro-1-fluorobenzene-induced delayed-type hypersensitivity.
Main Results:
- Irisflorentin exhibited no cellular toxicity up to 40 μM.
- Irisflorentin significantly reduced LPS-induced production of TNF-α, IL-6, and IL-12p70 by DCs.
- Irisflorentin inhibited the expression of MHC class II, CD40, and CD86 on LPS-stimulated DCs.
- Irisflorentin suppressed LPS-stimulated DC-induced T-cell proliferation.
- Irisflorentin interfered with LPS-induced activation of IκB kinase, JNK, p38, and NF-κB p65 nuclear translocation.
- Irisflorentin treatment weakened 2,4-dinitro-1-fluorobenzene-induced delayed-type hypersensitivity.
Conclusions:
- Irisflorentin effectively modulates dendritic cell maturation and function.
- Irisflorentin possesses anti-inflammatory properties by inhibiting key immune signaling pathways.
- Irisflorentin demonstrates potential as an immunotherapeutic adjuvant for managing hypersensitivity responses.
Abstract:
Irisflorentin is an isoflavone component derived from the roots of Belamcanda chinensis (L.) DC. In traditional Chinese medicine, this herb has pharmacological properties to treat inflammatory disorders. Dendritic cells (DCs) are crucial modulators for the development of optimal T-cell immunity and maintenance of tolerance. Aberrant activation of DCs can induce harmful immune responses, and so agents that effectively improve DC properties have great clinical value. We herein investigated the effects of irisflorentin on lipopolysaccharide (LPS)-stimulated maturation of mouse bone marrow-derived DCs in vitro and in the contact hypersensitivity response (CHSR) in vivo. Our results demonstrated that treatment with up to 40 μM irisflorentin does not cause cellular toxicity. Irisflorentin significantly lessened the proinflammatory cytokine production (tumor necrosis factor-α, interleukin-6, and interleukin-12p70) by LPS-stimulated DCs. Irisflorentin also inhibited the expression of LPS-induced major histocompatibility complex class II and costimulatory molecules (CD40 and CD86) on LPS-stimulated DCs. In addition, irisflorentin diminished LPS-stimulated DC-elicited allogeneic T-cell proliferation. Furthermore, irisflorentin significantly interfered with LPS-induced activation of IκB kinase, c-Jun N-terminal kinase, and p38, as well as the nuclear translocation of NF-κB p65. Subsequently, treatment with irisflorentin obviously weakened 2,4-dinitro-1-fluorobenzene-induced delayed-type hypersensitivity. These findings suggest new insights into the role of irisflorentin as an immunotherapeutic adjuvant through its capability to modulate the properties of DCs.
